

By: Representatives Scoggin, Boyd (19th),
Lancaster, Byrd

To: Drug Policy

HOUSE BILL NO. 364

1 AN ACT TO AMEND SECTION 41-29-113, MISSISSIPPI CODE OF 1972,
2 TO ADD KRATOM AND TIANEPTINE TO SCHEDULE I OF THE UNIFORM
3 CONTROLLED SUBSTANCES ACT; AND FOR RELATED PURPOSES.

4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI:

5 **SECTION 1.** Section 41-29-113, Mississippi Code of 1972, is
6 amended as follows:

7 41-29-113.

8 **SCHEDULE I**

9 (a) Schedule I consists of the drugs and other substances,
10 by whatever official name, common or usual name, chemical name, or
11 brand name designated, that is listed in this section.

12 (b) **Opiates.** Unless specifically excepted or unless listed
13 in another schedule, any of the following opiates, including their
14 isomers, esters, ethers, salts and salts of isomers, esters and
15 ethers, whenever the existence of these isomers, esters, ethers
16 and salts is possible within the specific chemical designation:

17 (1) Acetyl-alpha-methylfentanyl
18 (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);



19 (2) Acetylmethadol;
20 (3) Acetyl fentanyl
21 (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
22 (4) Acryl fentanyl
23 (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide), also known as
24 acryloylfentanyl;
25 (5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)
26 cyclohexylmethyl]benzamide);
27 (6) Allylprodine;
28 (7) Alphacetylmethadol, except levo-alphacetylmethadol
29 (levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM);
30 (8) Alphameprodine;
31 (9) Alphamethadol;
32 (10) Alpha-Methylfentanyl
33 (N-[1-alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionanilide;
34 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine);
35 (11) Alpha-Methylthiofentanyl
36 (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide
37);
38 (12) Benzethidine;
39 (13) Betacetylmethadol;
40 (14) Beta-Hydroxyfentanyl
41 (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);



42 (15) Beta-Hydroxy-3-methylfentanyl
43 (N-[1-(2-hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-phenylpr
44 opanamide);
45 (16) Beta-Hydroxythiofentanyl
46 (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpr
47 opionamide);
48 (17) Betameprodine;
49 (18) Betamethadol;
50 (19) Beta-Methyl fentanyl
51 (N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide), also
52 known as β -methyl fentanyl;
53 (20) Beta'-Phenyl fentanyl
54 (N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide), also
55 known as β' -phenyl fentanyl or 3-phenylpropanoyl fentanyl;
56 (21) Betaprodine;
57 (22) Butyrl fentanyl
58 (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide);
59 (23) Clonitazene;
60 (24) Crotonyl fentanyl
61 ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide);
62 (25) Cyclopentyl fentanyl
63 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);
64 (26) Cyclopropyl fentanyl
65 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
66 (27) Dextromoramide;



- 67 (28) Diampromide;
- 68 (29) Diethylthiambutene;
- 69 (30) Difenoxin;
- 70 (31) Dimenoxadol;
- 71 (32) Dimepheptanol;
- 72 (33) Dimethylthiambutene;
- 73 (34) Dioxaphetyl butyrate;
- 74 (35) Dipipanone;
- 75 (36) Ethylmethylthiambutene;
- 76 (37) Etonitazene;
- 77 (38) Etoxeridine;
- 78 (39) Fentanyl carbamate
- 79 (ethyl(1-phenethylpiperidin-4-yl)(phenyl)carbamate);
- 80 (40) Fentanyl-related substances, meaning any substance
- 81 not otherwise listed under another schedule and for which no
- 82 exemption or approval is in effect under Section 505 of the
- 83 Federal Food, Drug, and Cosmetic Act [21 USC 355] that is
- 84 structurally related to fentanyl by one or more of the following
- 85 modifications:
- 86 (A) Replacement of the phenyl portion of the
- 87 phenethyl group by any monocycle, whether or not further
- 88 substituted in or on the monocycle;
- 89 (B) Substitution in or on the phenethyl group with
- 90 alkyl, alkenyl, alkoxy, hydroxyl, halo, haloalkyl, amino or nitro
- 91 groups;



92 (C) Substitution in or on the piperidine ring with
93 alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, halo, haloalkyl,
94 amino or nitro groups;

95 (D) Replacement of the aniline ring with any
96 aromatic monocycle whether or not further substituted in or on the
97 aromatic monocycle; and/or

98 (E) Replacement of the N-propionyl group by
99 another acyl group.

100 (41) 4-Fluoroisobutyryl fentanyl
101 (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide),
102 also known as para-fluoroisobutyryl fentanyl);

103 (42) 2'-Fluoro ortho-fluorofentanyl
104 (N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)
105 propionamide), also known as 2'-fluoro 2-fluorofentanyl);

106 (43) Furanyl fentanyl
107 (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide);

108 (44) Furethidine;

109 (45) Hydroxypethidine;

110 (46) Isobutyryl fentanyl
111 (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide);

112 (47) Isotonitazene (N,N-diethyl-2-(2-(4
113 isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);

114 (48) Ketobemidone (including the optical and geometric
115 isomers);

116 (49) Levomoramide;



117 (50) Levophenacetylmorphan;
118 (51) Methoxyacetyl fentanyl
119 (2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
120 (52) 4'-Methyl acetyl fentanyl
121 (N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide);
122 (53) 3-Methylfentanyl
123 (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);
124 (54) 3-Methylthiofentanyl (N-[3-methyl-1-
125 (2-thienylethyl)-4-piperidinyl]-N-phenylpropanamide);
126 (55) Morpheridine;
127 (56) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
128 (57) MT-45
129 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);
130 (58) Noracymethadol;
131 (59) Norlevorphanol;
132 (60) Normethadone;
133 (61) Norpipanone;
134 (62) Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-
135 (1-phenethylpiperidin-4-yl)acetamide);
136 (63) Ortho-Fluoroacryl fentanyl
137 (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)acrylamide);
138 (64) Ortho-Fluorobutyryl fentanyl
139 (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide), also
140 known as 2-fluorobutyryl fentanyl;



141 (65) Ortho-Fluorofentanyl
142 (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide),
143 also known as 2-fluorofentanyl;
144 (66) Ortho-Fluoroisobutyryl fentanyl
145 (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
146 (67) Ortho-Methyl acetylfentanyl
147 (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide), also
148 known as 2-methyl acetylfentanyl;
149 (68) Ortho-Methyl methoxyacetyl fentanyl
150 (2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)
151 acetamide), also known as 2-methyl methoxyacetyl fentanyl;
152 (69) Para-Chloroisobutyryl fentanyl
153 (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
154 (70) Para-Fluorobutyryl fentanyl
155 (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);
156 (71) Para-Fluorofentanyl (N-(4-fluorophenyl)
157 -N-[1-(2-phenylethyl)-4-piperidinyl]propanamide);
158 (72) Para-Fluoro furanyl fentanyl N-(4-fluorophenyl)-N-
159 (1-phenethylpiperidin-4-yl)furan-2-carboxamide);
160 (73) Para-Methoxybutyryl fentanyl
161 (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);
162 (74) Para-Methylfentanyl
163 (N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide),
164 also known as 4-methylfentanyl);



165 (75) PEPAP
166 (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
167 (76) Phenadoxone;
168 (77) Phenampromide;
169 (78) Phenomorphan;
170 (79) Phenoperidine;
171 (80) Phenyl fentanyl
172 (N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide), also known as
173 benzoyl fentanyl;
174 (81) Piritramide;
175 (82) Proheptazine;
176 (83) Properidine;
177 (84) Propiram;
178 (85) Racemoramide;
179 (86) Tetrahydrofuranlyl fentanyl
180 (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-
181 carboxamide);
182 (87) Thiofentanyl
183 (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]propanamide);
184 (88) Thiofuranyl fentanyl
185 (N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide),
186 also known as 2-thiofuranyl fentanyl or thiophene fentanyl;
187 (89) Tilidine;
188 (90) Trimeperidine;
189 (91) U-47700, (3,4-dichloro-N-



190 [2-(dimethylamino)cyclohexyl]-N-methylbenzamide);

191 (92) Valeryl fentanyl

192 (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide).

193 (93) Tianeptine and any salt, sulfate, free acid, or
194 other preparation of Tianeptine, and any salt, sulfate, free acid,
195 compound, derivative, precursor, or preparation thereof which is
196 substantially chemically equivalent or identical with Tianeptine.

197 (c) **Opium derivatives.** Unless specifically excepted or
198 unless listed in another schedule, any of the following opium
199 derivatives, their salts, isomers and salts of isomers, whenever
200 the existence of these salts, isomers and salts of isomers is
201 possible within the specific chemical designation:

202 (1) Acetorphine;

203 (2) Acetyldihydrocodeine;

204 (3) Benzylmorphine;

205 (4) Codeine methylbromide;

206 (5) Codeine-N-Oxide;

207 (6) Cyrenorphine;

208 (7) Desomorphine;

209 (8) Dihydromorphine;

210 (9) Drotebanol;

211 (10) Etorphine (except hydrochloride salt);

212 (11) Heroin;

213 (12) Hydromorphanol;

214 (13) Methyldesorphine;



- 215 (14) Methyldihydromorphine;
- 216 (15) Monoacetylmorphine;
- 217 (16) Morphine methylbromide;
- 218 (17) Morphine methylsulfonate;
- 219 (18) Morphine-N-Oxide;
- 220 (19) Myrophine;
- 221 (20) Nicocodeine;
- 222 (21) Nicomorphine;
- 223 (22) Normorphine;
- 224 (23) Pholcodine;
- 225 (24) Thebacon.

226 (d) **Hallucinogenic substances.** Unless specifically excepted
227 or unless listed in another schedule, any material, compound,
228 mixture or preparation which contains any quantity of the
229 following substances, their salts, isomers (whether optical,
230 positional, or geometric) and salts of isomers, whenever the
231 existence of these salts, isomers and salts of isomers is possible
232 within the specific chemical designation:

- 233 (1) Alpha-ethyltryptamine;
- 234 (2) 4-bromo-2,5-dimethoxy-amphetamine;
- 235 (3) 4-bromo-2,5-dimethoxyphenethylamine;
- 236 (4) 2,5-dimethoxyamphetamine;
- 237 (5) 2,5-dimethoxy-4-ethylamphetamine (DOET);
- 238 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine
239 (2C-T-7);



- 240 (7) 4-methoxyamphetamine;
- 241 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 242 (9) 4-methyl-2,5-dimethoxy-amphetamine;
- 243 (10) 3,4-methylenedioxy amphetamine;
- 244 (11) 3,4-methylenedioxymethamphetamine (MDMA);
- 245 (12) 3,4-methylenedioxy-N-ethylamphetamine (also known
- 246 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl
- 247 MDA, MDE, MDEA);
- 248 (13) N-hydroxy-3,4-methylenedioxyamphetamine (also
- 249 known as N-hydroxy MDA, N-OHMDA, and
- 250 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine);
- 251 (14) 3,4,5-trimethoxy amphetamine;
- 252 (15) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
- 253 (16) Alpha-methyltryptamine (also known as AMT);
- 254 (17) Bufotenine;
- 255 (18) Diethyltryptamine;
- 256 (19) Dimethyltryptamine;
- 257 (20) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
- 258 (21) Ibogaine;
- 259 (22) Lysergic acid diethylamide (LSD);
- 260 (23) (A) Marijuana (Hemp as defined and regulated
- 261 under Sections 69-25-201 through 69-25-221 and Cannabidiol
- 262 contained in a legend drug product approved by the Federal Food
- 263 and Drug Administration or obtained under Section 41-29-136 are
- 264 exempt under Schedule I);



265 (B) Hashish;
266 (24) Mescaline;
267 (25) Parahexyl;
268 (26) Peyote;
269 (27) N-ethyl-3-piperidyl benzilate;
270 (28) N-methyl-3-piperidyl benzilate;
271 (29) Psilocybin;
272 (30) Psilocyn;
273 (31) Tetrahydrocannabinols, meaning
274 tetrahydrocannabinols contained in a plant of the genus Cannabis
275 (cannabis plant), as well as the synthetic equivalents of the
276 substances contained in the cannabis plant, or in the resinous
277 extractives of such plant, and/or synthetic substances,
278 derivatives, and their isomers with similar chemical structure and
279 pharmacological activity to those substances contained in the
280 plant such as the following:

- 281 (A) 1 cis or trans tetrahydrocannabinol;
282 (B) 6 cis or trans tetrahydrocannabinol;
283 (C) 3,4 cis or trans tetrahydrocannabinol.

284 (Since nomenclature of these substances is not
285 internationally standardized, compounds of these structures,
286 regardless of atomic positions, are covered.)

287 ("Tetrahydrocannabinols" excludes dronabinol and nabilone.)
288 For purposes of this paragraph, tetrahydrocannabinols do not



289 include hemp or hemp products regulated under Sections 69-25-201
290 through 69-25-221.

291 However, the following products are exempted from control:

292 (i) THC-containing industrial products made
293 from cannabis stalks (e.g., paper, rope and clothing);

294 (ii) Processed cannabis plant materials used
295 for industrial purposes, such as fiber retted from cannabis stalks
296 for use in manufacturing textiles or rope;

297 (iii) Animal feed mixtures that contain
298 sterilized cannabis seeds and other ingredients (not derived from
299 the cannabis plant) in a formula designed, marketed and
300 distributed for nonhuman consumption;

301 (iv) Personal care products that contain oil
302 from sterilized cannabis seeds, such as shampoos, soaps, and body
303 lotions (if the products do not cause THC to enter the human
304 body);

305 (v) Hemp as regulated under Sections
306 69-25-201 through 69-25-221; and

307 (vi) Any product derived from the hemp plant
308 designed for human ingestion and/or consumption that is approved
309 by the United States Food and Drug Administration;

310 (32) Phencyclidine;

311 (33) Ethylamine analog of phencyclidine (PCE);

312 (34) Pyrrolidine analog of phencyclidine (PHP, PCPy);

313 (35) Thiophene analog of phencyclidine;



314 (36) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine (TCPy);
315 (37) 4-methylmethcathinone (mephedrone);
316 (38) 3,4-methylenedioxypropylvalerone (MDPV);
317 (39) 2-(2,5-dimethoxy-4-ethylphenyl)ethanamine (2C-E);
318 (40) 2-(2,5-dimethoxy-4-methylphenyl)ethanamine (2C-D);
319 (41) 2-(4-chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
320 (42) 2-(4-iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
321 or 2,5-dimethoxy-4-iodophenethylamine;
322 (43) 2-[4-(ethylthio)-2,5-dimethoxyphenyl]ethanamine
323 (2C-T-2);
324 (44)
325 2-[4-(isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);
326 (45) 2-(2,5-dimethoxyphenyl)ethanamine (2C-H);
327 (46) 2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
328 (47) 2-(2,5-dimethoxy-4-(n)-propylphenyl)ethanamine
329 (2C-P);
330 (48) 3,4-methylenedioxy-N-methylcathinone (methyldone);
331 (49)
332 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
333 (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);
334 (50)
335 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
336 (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);
337 (51)
338 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine or



339 N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I;
340 Cimbi-5);

341 (52) 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,
342 4-benzodiazepin-2-one (also known as Phenazepam);

343 (53) 7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8,
344 11,12-tetraazatricyclo[8.3.0.0]trideca-2(6),4,7,10,12-pentaene
345 (also known as Etizolam);

346 (54) Salvia divinorum;

347 (55) Synthetic cannabinoids. Unless specifically
348 excepted or unless listed in another schedule, any material,
349 compound, mixture, or preparation which contains any quantity of a
350 synthetic cannabinoid found in any of the following chemical
351 groups, whether or not substituted to any extent, or any of those
352 groups which contain any synthetic cannabinoid salts, isomers, or
353 salts of isomers, whenever the existence of such salts, isomers,
354 or salts of isomers is possible within the specific chemical
355 designation, including all synthetic cannabinoid chemical
356 analogues in such groups:

357 (A) (6aR,10aR)-9-(hydroxymethyl)-6,
358 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]
359 chromen-1-ol (also known as HU-210 or
360 1,1-dimethylheptyl-11-hydroxy-delta8-tetrahydrocannabinol);

361 (B) Naphthoylindoles and naphthylmethylindoles,
362 being any compound structurally derived from 3-(1-naphthoyl)indole
363 or 1H-indol-3-yl-(1-naphthyl)methane, whether or not substituted



364 in the indole ring to any extent, or in the naphthyl ring to any
365 extent;

366 (C) Naphthoylpyrroles, being any compound
367 structurally derived from 3-(1-naphthoyl)pyrrole, whether or not
368 substituted in the pyrrole ring to any extent, or in the naphthyl
369 ring to any extent;

370 (D) Naphthylmethylindenes, being any compound
371 structurally derived from 1-(1-naphthylmethyl)indene, whether or
372 not substituted in the indene ring to any extent or in the
373 naphthyl ring to any extent;

374 (E) Phenylacetylindoles, being any compound
375 structurally derived from 3-phenylacetylindole, whether or not
376 substituted in the indole ring to any extent or in the phenyl ring
377 to any extent;

378 (F) Cyclohexylphenols, being any compound
379 structurally derived from 2-(3-hydroxycyclohexyl)phenol, whether
380 or not substituted in the cyclohexyl ring to any extent or in the
381 phenolic ring to any extent;

382 (G) Benzoylindoles, whether or not substituted in
383 the indole ring to any extent or in the phenyl ring to any extent;

384 (H) Adamantoylindoles, whether or not substituted
385 in the indole ring to any extent or in the adamantoyl ring system
386 to any extent;



387 (I) Tetrahydro derivatives of cannabinal and
388 3-alkyl homologues of cannabinal or of its tetrahydro derivatives,
389 except where contained in cannabis or cannabis resin;

390 (J) 3-Cyclopropylmethanone indole or
391 3-Cyclobutylmethanone indole or 3-Cyclopentylmethanone indole by
392 substitution at the nitrogen atom of the indole ring, whether or
393 not further substituted in the indole ring to any extent, whether
394 or not substituted on the cyclopropyl, cyclobutyl or cyclopentyl
395 rings to any extent;

396 (K) Quinoliny ester indoles, being any compound
397 structurally derived from 1H-indole-3carboxylic acid-8-quinoliny
398 ester, whether or not substituted in the indole ring to any extent
399 or the quinolone ring to any extent;

400 (L) 3-carboxamide-1H-indazoles, whether or not
401 substituted in the indazole ring to any extent and substituted to
402 any degree on the carboxamide nitrogen and
403 3-carboxamide-1H-indoles, whether or not substituted in the indole
404 ring to any extent and substituted to any degree on the
405 carboxamide nitrogen;

406 (M) Cycloalkanemethanone Indoles, whether or not
407 substituted at the nitrogen atom on the indole ring, whether or
408 not further substituted in the indole ring to any extent, whether
409 or not substituted on the cycloalkane ring to any extent;



410 (56) Naphthalen-1-yl
411 1-(5-fluoropentyl)-1H-indole-3-carboxylate, also known as NM2201
412 or CBL2201;

413 (57) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-
414 pyrrolo[2,3-b]pyridine-3-carboxamide, also known as
415 5F-CUMYL-P7AICA;

416 (58) 1-(4-methoxyphenyl)-N-methylpropan-2-amine, also
417 known as para-methoxymethamphetamine or PMMA.

418 (e) **Depressants.** Unless specifically excepted or unless
419 listed in another schedule, any material, compound, mixture, or
420 preparation which contains any quantity of the following
421 substances having a depressant effect on the central nervous
422 system, including their salts, isomers, and salts of isomers,
423 whenever the existence of such salts, isomers, and salts of
424 isomers is possible within the specific chemical designation:

425 (1) Clonazepam,
426 6-(2-chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]
427 benzodiazepine;

428 (2) Flualprazolam,
429 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4
430]benzodiazepine;

431 (3) Flubromazepam,
432 7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one;

433 (4) Flubromazolam,



434 8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]
435 benzodiazepin;

436 (5) Gamma-hydroxybutyric acid (other names include:
437 GHB, gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic
438 acid; sodium oxybate; sodium oxybutyrate);

439 (6) Mecloqualone;

440 (7) Methaqualone.

441 (f) **Stimulants.** Any material, compound, mixture or
442 preparation which contains any quantity of the following central
443 nervous system stimulants including optical salts, isomers and
444 salts of isomers unless specifically excepted or unless listed in
445 another schedule:

446 (1) Aminorex;

447 (2) N-benzylpiperazine (also known as BZP and
448 1-benzylpiperazine);

449 (3) Cathinone;

450 (4) Fenethylamine;

451 (5) Methcathinone;

452 (6) 4-methylaminorex (also known as
453 2-amino-4-methyl-5-phenyl-2-oxazoline);

454 (7) N-ethylamphetamine;

455 (8) Any material, compound, mixture or preparation
456 which contains any quantity of N,N-dimethylamphetamine. (Other
457 names include: N,N,-alpha-trimethyl-benzeneethanamine and
458 N,N-alpha-trimethylphenethylamine);



459 (9) **Synthetic cathinones.** (A) Unless listed in
460 another schedule, any compound other than bupropion that is
461 structurally derived from 2-Amino-1-phenyl-1-propanone by
462 modification in any of the following ways:

463 (i) By substitution in the phenyl ring to any
464 extent with alkyl, alkoxy, alkylendioxy, haloalkyl or halide
465 substituents, whether or not further substituted in the phenyl
466 ring by one or more other univalent substituents;

467 (ii) By substitution at the 3-position with
468 an alkyl substituent;

469 (iii) By substitution at the nitrogen atom
470 with alkyl or dialkyl groups, or by inclusion of the nitrogen atom
471 in a cyclic structure.

472 (B) The compounds covered in this paragraph (9)
473 include, but are not limited to, any material, compound, mixture
474 or preparation which contains any quantity of a synthetic
475 cathinone found in any of the following compounds, whether or not
476 substituted to any extent, or any of these compounds which contain
477 any synthetic cathinone, or salts, isomers, or salts of isomers,
478 whenever the existence of such salts, isomers or salts of isomers
479 is possible, unless specifically excepted or listed in another
480 schedule:

481 (i) 4-methyl-N-ethylcathinone ("4-MEC");

482 (ii) 4-methyl-alpha-pyrrolidinopropiophenone
483 ("4-MePPP");



484 (iii) Alpha-pyrrolidinopentiophenone
485 ("α-PVP");
486 (iv)
487 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one ("butylone");
488 (v) 2-(methylamino)-1-phenylpentan-1-one
489 ("pentedrone");
490 (vi)
491 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one
492 ("pentylone");
493 (vii) 4-fluoro-N-methylcathinone ("4-FMC");
494 (viii) 3-fluoro-N-methylcathinone ("3-FMC");
495 (ix)
496 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one ("naphyrone");
497 (x) Alpha-pyrrolidinobutiophenone ("α-PBP");
498 and
499 (xi)
500 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one
501 (N-ethylpentylone, ephylone).
502 (10) (A) Mitragynine; and
503 (B) 7-hydroxymitragynine.

504 **SECTION 2.** This act shall take effect and be in force from
505 and after July 1, 2023.

